Key result
SLAMF7 knockdown attenuates aortic valve calcification and thickening in preclinical models via BMP-2/Smad1/5 inhibition.
Why the study?
No effective pharmacological therapy currently delays the progression of calcific aortic valve disease, and the role and mechanisms of SLAMF7 in aortic valve calcification remained to be elucidated.
Does targeted knockdown of SLAMF7 mitigate aortic valve thickening and calcification in ApoE−/− mice fed a high-cholesterol diet?
Does targeted knockdown of SLAMF7 mitigate aortic valve thickening and calcification in ApoE−/− mice fed a high-cholesterol diet?
Identifies the SLAMF7/BMP-2/Smad1/5 signaling axis as a key driver of aortic valve calcification, suggesting SLAMF7 as a potential therapeutic target for calcific aortic valve disease.
Answers are grounded in this paper and cite their sources.
SLAMF7 inhibition should not yet change aortic stenosis management; leaves open its investigation as a disease-modifying target in prospective studies.
Calcific aortic valve disease (CAVD) is a common cardiovascular disorder for which no effective pharmacological therapy is currently available to delay its progression. This study investigated the role and underlying mechanisms of signaling lymphocytic activation molecule family member 7 (SLAMF7) in aortic valve calcification. We found that SLAMF7 was significantly upregulated in calcified human aortic valves and in human aortic valve interstitial cells (hVICs) undergoing osteogenic differentiation. Functionally, SLAMF7 overexpression accelerated the osteogenic phenotypic transformation of hVICs. In vivo, targeted knockdown of SLAMF7 using antisense oligonucleotides (ASOs) mitigated aortic valve thickening and calcification in apolipoprotein E-deficient (ApoE −/− ) mice fed a high-cholesterol diet. Mechanistically, SLAMF7 was associated with bone morphogenetic protein 2 (BMP-2), reduced its polyubiquitination, and enhanced its protein stability. Additional experiments implicated SMURF1 in the regulation of BMP-2 protein abundance and showed that SLAMF7 overexpression reduced the association between SMURF1 and BMP-2, suggesting a potential mechanism underlying BMP-2 stabilization. This stabilization activated the downstream BMP-2/Smad1/5 signaling cascade to drive hVIC osteogenesis, an effect reversed by BMP pathway inhibition. In conclusion, this study identifies the SLAMF7/BMP-2/Smad1/5 signaling axis as a key driver of aortic valve calcification. These findings provide novel mechanistic insights into the pathogenesis of this disease and suggest that targeting SLAMF7 may represent a potential therapeutic strategy for the management of CAVD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Calcific aortic valve disease (CAVD). Targeted knockdown of SLAMF7 using antisense oligonucleotides (ASOs) / SLAMF7 overexpression was evaluated on Aortic valve thickening, calcification, and hVIC osteogenic differentiation via BMP-2/Smad1/5 signaling. SLAMF7 knockdown with antisense oligonucleotides mitigated aortic valve thickening and calcification in ApoE-/- mice by preventing BMP-2 stabilization and Smad1/5 signaling activation.
Synapse has enriched 10 related papers. Consider them for comparative context: